Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 13(5): e0197952, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29782553

RESUMO

[This corrects the article DOI: 10.1371/journal.pone.0163619.].

2.
J Electrocardiol ; 50(6): 808-813, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28928044

RESUMO

The ECG plays a critical role in the thorough QT study. This clinical study is part of the assessment of proarrhythmic potential of drugs under the current regulatory paradigm. While the current paradigm has been successful in preventing drugs with unexpected QT prolongation or torsade risk from reaching the market, the focus on QT prolongation has likely resulted in potentially beneficial compounds with minimal torsade risk being dropped from development. The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative is developing and validating a new mechanistic-based paradigm for cardiac safety evaluation of drugs. The fourth component of CiPA uses ECG data in phase 1 clinical studies to confirm there are no unanticipated ion channel effects compared to nonclinical data. The J-Tpeak interval was identified as the best biomarker for differentiating QTc prolonging drugs with predominant hERG block from drugs with multichannel (hERG plus late sodium and/or calcium block). This manuscript describes ECG methods for J-Tpeak assessment and their relationship with the features of new ECG biomarkers for detecting multichannel effects under CiPA.


Assuntos
Algoritmos , Biomarcadores/análise , Bloqueadores dos Canais de Cálcio/farmacologia , Eletrocardiografia/métodos , Sistema de Condução Cardíaco/efeitos dos fármacos , Canais Iônicos/efeitos dos fármacos , Síndrome do QT Longo/induzido quimicamente , Síndrome do QT Longo/diagnóstico , Bloqueadores dos Canais de Potássio/farmacologia , Bloqueadores dos Canais de Sódio/farmacologia , Torsades de Pointes/induzido quimicamente , Torsades de Pointes/diagnóstico , Arritmias Cardíacas/induzido quimicamente , Arritmias Cardíacas/diagnóstico , Fenômenos Eletrofisiológicos , Frequência Cardíaca/efeitos dos fármacos , Frequência Cardíaca/fisiologia , Humanos , Fenetilaminas/farmacologia , Quinidina/farmacologia , Ranolazina/farmacologia , Sulfonamidas/farmacologia , Verapamil/farmacologia
3.
PLoS One ; 11(12): e0166925, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-28036330

RESUMO

BACKGROUND: Prolongation of the heart rate corrected QT (QTc) interval is a sensitive marker of torsade de pointes risk; however it is not specific as QTc prolonging drugs that block inward currents are often not associated with torsade. Recent work demonstrated that separate analysis of the heart rate corrected J-Tpeakc (J-Tpeakc) and Tpeak-Tend intervals can identify QTc prolonging drugs with inward current block and is being proposed as a part of a new cardiac safety paradigm for new drugs (the "CiPA" initiative). METHODS: In this work, we describe an automated measurement methodology for assessment of the J-Tpeakc and Tpeak-Tend intervals using the vector magnitude lead. The automated measurement methodology was developed using data from one clinical trial and was evaluated using independent data from a second clinical trial. RESULTS: Comparison between the automated and the prior semi-automated measurements shows that the automated algorithm reproduces the semi-automated measurements with a mean difference of single-deltas <1 ms and no difference in intra-time point variability (p for all > 0.39). In addition, the time-profile of the baseline and placebo-adjusted changes are within 1 ms for 63% of the time-points (86% within 2 ms). Importantly, the automated results lead to the same conclusions about the electrophysiological mechanisms of the studied drugs. CONCLUSIONS: We have developed an automated algorithm for assessment of J-Tpeakc and Tpeak-Tend intervals that can be applied in clinical drug trials. Under the CiPA initiative this ECG assessment would determine if there are unexpected ion channel effects in humans compared to preclinical studies. The algorithm is being released as open-source software. TRIAL REGISTRATION: NCT02308748 and NCT01873950.


Assuntos
Arritmias Cardíacas/induzido quimicamente , Arritmias Cardíacas/fisiopatologia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/fisiopatologia , Sistema de Condução Cardíaco/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Preparações Farmacêuticas/administração & dosagem , Algoritmos , Automação/métodos , Eletrocardiografia/métodos , Humanos , Síndrome do QT Longo/induzido quimicamente , Síndrome do QT Longo/fisiopatologia , Risco , Torsades de Pointes/induzido quimicamente , Torsades de Pointes/fisiopatologia
4.
PLoS One ; 11(12): e0163619, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-28036334

RESUMO

BACKGROUND: Drugs that prolong the heart rate corrected QT interval (QTc) on the electrocardiogram (ECG) by blocking the hERG potassium channel and also block inward currents (late sodium or L-type calcium) are not associated with torsade de pointes (e.g. ranolazine and verapamil). Thus, identifying ECG signs of late sodium current block could aid in the determination of proarrhythmic risk for new drugs. A new cardiac safety paradigm for drug development (the "CiPA" initiative) will involve the preclinical assessment of multiple human cardiac ion channels and ECG biomarkers are needed to determine if there are unexpected ion channel effects in humans. METHODS AND RESULTS: In this study we assess the ability of eight ECG morphology biomarkers to detect late sodium current block in the presence of QTc prolongation by analyzing a clinical trial where a selective hERG potassium channel blocker (dofetilide) was administered alone and then in combination with two late sodium current blockers (lidocaine and mexiletine). We demonstrate that late sodium current block has the greatest effect on the heart-rate corrected J-Tpeak interval (J-Tpeakc), followed by QTc and then T-wave flatness. Furthermore, J-Tpeakc is the only biomarker that improves detection of the presence of late sodium current block compared to using QTc alone (AUC: 0.83 vs. 0.72 respectively, p<0.001). CONCLUSIONS: Analysis of the J-Tpeakc interval can differentiate drug-induced multichannel block involving the late sodium current from selective hERG potassium channel block. Future methodologies assessing drug effects on cardiac ion channel currents on the ECG should use J-Tpeakc to detect the presence of late sodium current block. TRIAL REGISTRATION: NCT02308748 and NCT01873950.


Assuntos
Biomarcadores/metabolismo , Coração/efeitos dos fármacos , Bloqueadores dos Canais de Sódio/farmacologia , Sódio/metabolismo , Adulto , Bloqueadores dos Canais de Cálcio/farmacologia , Estudos Cross-Over , Eletrocardiografia/métodos , Canais de Potássio Éter-A-Go-Go/metabolismo , Feminino , Frequência Cardíaca/efeitos dos fármacos , Humanos , Lidocaína/farmacologia , Síndrome do QT Longo/metabolismo , Masculino , Mexiletina/farmacologia , Fenetilaminas/farmacologia , Bloqueadores dos Canais de Potássio/farmacologia , Sulfonamidas/farmacologia , Torsades de Pointes/metabolismo , Verapamil/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...